Hyunkyung Park1,2, Dong-Yeop Shin1, Inho Kim3, Sang-Kyun Sohn4, Youngil Koh1, Je-Hwan Lee5, Kyoo-Hyung Lee5, Dae-Young Kim5, Hyeong-Joon Kim6, Jae-Sook Ahn6, Jeong-Ok Lee7, Soo-Mee Bang7, June-Won Cheong8, Sang-Gon Park9, Seonyang Park1,10, Yoo Jin Lee11, Seo-Yeon Ahn6. 1. Department of Internal Medicine, Biomedical Research Institute, Cancer Research Institute, Seoul National University Hospital, Seoul, Republic of Korea. 2. Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Republic of Korea. 3. Department of Internal Medicine, Biomedical Research Institute, Cancer Research Institute, Seoul National University Hospital, Seoul, Republic of Korea ihkimmd@snu.ac.kr sksohn@knu.ac.kr. 4. Department of Internal Medicine, Kyungpook National University Hospital, Daegu, Republic of Korea ihkimmd@snu.ac.kr sksohn@knu.ac.kr. 5. Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. 6. Department of Internal Medicine, Chonnam National University, Hwasun Hospital, Hwasun, Republic of Korea. 7. Department of Internal Medicine, Seoul National University, Bundang Hospital, Seongnam, Republic of Korea. 8. Department of Internal Medicine, Yonsei University, Severance Hospital, Seoul, Republic of Korea. 9. Department of Internal Medicine, Chosun University Hospital, Gwangju, Republic of Korea. 10. Department of Internal Medicine, Inje University, Haeundae Paik Hospital, Busan, Republic of Korea. 11. Department of Internal Medicine, Kyungpook National University Hospital, Daegu, Republic of Korea.
Abstract
BACKGROUND/AIM: Droplet digital polymerase chain reaction (ddPCR) is an exact method of measuring nucleic acids. The aim of this prospective study was to evaluate minimal residual disease (MRD) using ddPCR in chronic myeloid leukemia (CML) patients. PATIENTS AND METHODS: Between May 2013 and November 2014, CML patients treated with nilotinib were enrolled in our study. BCR/ABL1 transcripts levels were evaluated using ddPCR at the first time of complete molecular response (CMR). We enrolled 15 patients from 7 Institutions. The treatment period and median follow-up period were 45 months and 47 months, respectively. RESULTS: Patients with a high level of BCR/ABL1 transcript had a greater tendency to lose the CMR during the follow-up period (p=0.095). In addition, patients with a low level of BCR/ABL1 transcript showed a longer duration of CMR compared to those with a high level (p=0.032). CONCLUSION: We found that ddPCR is a sensitive method for detecting MRD and that MRD could affect the duration of the treatment response. Copyright
BACKGROUND/AIM: Droplet digital polymerase chain reaction (ddPCR) is an exact method of measuring nucleic acids. The aim of this prospective study was to evaluate minimal residual disease (MRD) using ddPCR in chronic myeloid leukemia (CML) patients. PATIENTS AND METHODS: Between May 2013 and November 2014, CMLpatients treated with nilotinib were enrolled in our study. BCR/ABL1 transcripts levels were evaluated using ddPCR at the first time of complete molecular response (CMR). We enrolled 15 patients from 7 Institutions. The treatment period and median follow-up period were 45 months and 47 months, respectively. RESULTS:Patients with a high level of BCR/ABL1 transcript had a greater tendency to lose the CMR during the follow-up period (p=0.095). In addition, patients with a low level of BCR/ABL1 transcript showed a longer duration of CMR compared to those with a high level (p=0.032). CONCLUSION: We found that ddPCR is a sensitive method for detecting MRD and that MRD could affect the duration of the treatment response. Copyright
Authors: A Venditti; F Buccisano; G Del Poeta; L Maurillo; A Tamburini; C Cox; A Battaglia; G Catalano; B Del Moro; L Cudillo; M Postorino; M Masi; S Amadori Journal: Blood Date: 2000-12-01 Impact factor: 22.113
Authors: Philip A Thompson; Constantine S Tam; Susan M O'Brien; William G Wierda; Francesco Stingo; William Plunkett; Susan C Smith; Hagop M Kantarjian; Emil J Freireich; Michael J Keating Journal: Blood Date: 2015-10-22 Impact factor: 22.113
Authors: Rüdiger Hehlmann; Martin C Müller; Michael Lauseker; Benjamin Hanfstein; Alice Fabarius; Annette Schreiber; Ulrike Proetel; Nadine Pletsch; Markus Pfirrmann; Claudia Haferlach; Susanne Schnittger; Hermann Einsele; Jolanta Dengler; Christiane Falge; Lothar Kanz; Andreas Neubauer; Michael Kneba; Frank Stegelmann; Michael Pfreundschuh; Cornelius F Waller; Karsten Spiekermann; Gabriela M Baerlocher; Gerhard Ehninger; Dominik Heim; Hermann Heimpel; Christoph Nerl; Stefan W Krause; Dieter K Hossfeld; Hans-Jochem Kolb; Joerg Hasford; Susanne Saußele; Andreas Hochhaus Journal: J Clin Oncol Date: 2013-12-02 Impact factor: 44.544
Authors: J Flores-Montero; L Sanoja-Flores; B Paiva; N Puig; O García-Sánchez; S Böttcher; V H J van der Velden; J-J Pérez-Morán; M-B Vidriales; R García-Sanz; C Jimenez; M González; J Martínez-López; A Corral-Mateos; G-E Grigore; R Fluxá; R Pontes; J Caetano; L Sedek; M-C Del Cañizo; J Bladé; J-J Lahuerta; C Aguilar; A Bárez; A García-Mateo; J Labrador; P Leoz; C Aguilera-Sanz; J San-Miguel; M-V Mateos; B Durie; J J M van Dongen; A Orfao Journal: Leukemia Date: 2017-01-20 Impact factor: 11.528
Authors: Joost H van Ginkel; Manon M H Huibers; Robert J J van Es; Remco de Bree; Stefan M Willems Journal: BMC Cancer Date: 2017-06-19 Impact factor: 4.430
Authors: Bavo Verhaegen; Koen De Reu; Lieven De Zutter; Karen Verstraete; Marc Heyndrickx; Els Van Coillie Journal: Toxins (Basel) Date: 2016-05-18 Impact factor: 4.546